Surgical Neurology
Volume 69, Issue 1 , Pages 46-50 , January 2008

Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors

  • Mizuhiko Terasaki, MD, PhD

      Affiliations

    • Department of Neurosurgery, Kurume University School of Medicine, Fukuoka 830-0011, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 942 35 3311; fax: +81 942 38 8179.
    • ,
  • Eric Bouffet, MD

      Affiliations

    • Pediatric Brain Tumor Program, Hospital for Sick Children, Toronto, Canada M5G 1X8
    • ,
  • Hiroshi Katsuki, MD

      Affiliations

    • Department of Neurosurgery, Kurume University School of Medicine, Fukuoka 830-0011, Japan
    • ,
  • Shintaro Fukushima, MD

      Affiliations

    • Department of Neurosurgery, Kurume University School of Medicine, Fukuoka 830-0011, Japan
    • ,
  • Minoru Shigemori, MD, PhD

      Affiliations

    • Department of Neurosurgery, Kurume University School of Medicine, Fukuoka 830-0011, Japan

Received 12 January 2007 ,Accepted 18 July 2007.

References 

  1. Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol. 1996;14:1922–1927
  2. Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol. 2006;24:1273–1280
  3. Chamberlain MC. Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. Pediatr Neurol. 2001;24:117–121
  4. Chamberlain MC. Recurrent supratentorial malignant gliomas in children; long-term salvage therapy with oral etoposide. Arch Neurol. 1997;54:554–558
  5. Chamberlain MC. Recurrent brainstem gliomas treated with oral VP-16. J Neuro-Oncol. 1993;15:133–139
  6. Chamberlain MC, Jaekle KA. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol. 1995;13:2072–2076
  7. Dehdashti AR, Hegi ME, Regli L, Pica A, Stupp R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Focus. 2006;20:e6
  8. Guyotat J, Signorelli F, Frappaz D, Madarassy G, Ricci AC, Bret P. Is reoperation for recurrence of glioblastoma justified?. Oncol Rep. 2000;7:899–904
  9. Kleihues P, Cavenee WK. In: Pathology & genetics; tumours of the nervous system. Lyon: IARC press; 2000;p. 9–54
  10. Korones DN, Benita-Weiss M, Coyle TE, Mechtler L, Bushunow P, Evans B, et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer. 2003;97:1963–1968
  11. Korones DN, Benita-Weiss M, Coyle TE, Mechtler L, Bushunow P, Evans B, et al. A phase II study of temozolomide and oral VP-16 for adults with recurrent malignant glioma. Proc ASCO. 2003;447
  12. Korones DN, Benita-Weiss M, Coyle TE, Bushunow P, Mechtler L, Friedman H. A phase II study of temozolomide and oral VP-16 for adults with recurrent glioma—final results. ASCO. 2006;1565;[Abstr]
  13. Korones DN, Smith A, Foreman N, Bouffet E. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. Pediatr Blood Cancer. 2006;47:37–41
  14. Lilley ER. Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. Cancer Res. 1990;50:284–287
  15. Needle MN, Molloy PT, Geyer JR, Herman-Liu A, Belasco JB, Goldwein JW, et al. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol. 1997;29:28–32
  16. Patel VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, Johnson SP, et al. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res. 2000;6:4154–4157
  17. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, et al. Changing paradigms—an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11:165–180
  18. Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol. 2005;23:4235–4236[Author reply 4236]
  19. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588–593
  20. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse, Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762–2771

PII: S0090-3019(07)00920-2

doi: 10.1016/j.surneu.2007.07.066

Surgical Neurology
Volume 69, Issue 1 , Pages 46-50 , January 2008

Article Tools

* Image Usage & Resolution